Impact of Topical Sinonasal Budesonide Irrigation on Hypothalamic-Pituitary-Adrenal Axis Function
1 other identifier
interventional
2
1 country
1
Brief Summary
Chronic rhinosinusitis (CRS) is a complex inflammatory disease that is treated primarily with sinus surgery and the long-term use of topical steroid therapy. Budesonide irrigation is a common method of topical steroid treatment for these patients. However, the effects of budesonide irrigation on the hypothalamic-pituitary-adrenal (HPA) axis in patients with CRS following sinus surgery, is as of yet not defined. The objective of this study is to determine if topical sinonasal budesonide steroid irrigation leads to acute recoverable and/or long-term suppression of the HPA axis. Participants in this prospective cohort study will have CRS and have recently undergone endoscopic sinus surgery. They will also have had planned use of budesonide irrigations as their postoperative medical treatment. The acute effects of this treatment on the HPA axis will be evaluated using serial serum cortisol measurements both the day before and the day of the first budesonide irrigation. The long-term effect of sinonasal budesonide irrigation will be evaluated using both a pre- and post-treatment adrenocorticotropic hormone (ACTH) stimulation test as well as repeated urine free cortisol levels over the length of the study. The results will determine the need for additional steroids when patients stop treatment or with a physiologic stressful event.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Dec 2010
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2010
CompletedFirst Submitted
Initial submission to the registry
June 12, 2011
CompletedFirst Posted
Study publicly available on registry
June 15, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2012
CompletedMay 18, 2012
May 1, 2012
1.4 years
June 12, 2011
May 16, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Serum cortisol levels before and after treatment
12 months
ACTH stimulation test cortisol level
12 months
Urinary Free Cortisol Levels
Every 3 months
Study Arms (1)
Budesonide
EXPERIMENTALInterventions
A budesonide (1 mg) in saline (240 mL) irrigation solution is applied to the sinonasal cavities twice daily. 120 mL of the solution is applied via irrigation in the AM, and 120 mL again in the PM.
Eligibility Criteria
You may qualify if:
- Consenting adult patients (age ≥18) who are diagnosed with CRS
- Patient already determined to need surgical treatment having failed medical management
- Patients planned to be treated with budesonide irrigations as postoperative maintenance therapy
You may not qualify if:
- Patients with pre-operative symptoms and signs of HPA dysfunction
- Patients with signs and symptoms of untreated endocrine disorders such as hypothyroidism, hypopituitarism, hypogonadism. Screening for thyroid disease will be done with a TSH, T3 and free T4 for each participant.
- Patients with known history of liver disease or abnormal AST/ALT lab tests
- Any history of oral glucocorticoid use in the past 4 months
- Patients with a known history of glaucoma
- Patients with known tuberculosis (TB)- active or latent
- Patients taking drugs that affect cortisol synthesis (mifepristomine, itraconazole, ketoconazole, erythromycin, clarithromycin, cimetidine) or protein binding drugs (estrogens and androgens)
- A known sensitivity to topical budesonide
- Pregnant and/or breast feeding woman
- Presence of multiple co-morbidities such as poorly controlled diabetes, chronic renal failure, hepatic failure
- Inability to provide informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ottawa Hospital Riverside Campus
Ottawa, Ontario, K1H 4E9, Canada
Study Officials
- PRINCIPAL INVESTIGATOR
Kilty Shaun, MD
OHRI
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 12, 2011
First Posted
June 15, 2011
Study Start
December 1, 2010
Primary Completion
May 1, 2012
Study Completion
May 1, 2012
Last Updated
May 18, 2012
Record last verified: 2012-05